REGENXBIO, which is developing gene therapies for rare diseases with a proprietary delivery platform, raised the proposed deal size for its upcoming IPO on Wednesday. The Rockville, MD-based company now plans to raise $122 million by offering 5.6 million shares at $22 per share. The company had previously filed to offer the same number of shares at a range of $17 to $19. At $22 per share, REGENXBIO would raise 22% greater proceeds than previously anticipated.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
